This review article addresses some of the complex issues surrounding antidepressant drug usage among elderly depressives. While primarily geared toward the psychiatrist in general practice, the article provides useful information for the nonpsychiatric physician who is frequently called upon to evaluate and treat affective disorders in the geriatric population. Since tricyclic antidepressants and lithium are the most commonly used psychotropic drugs in the treatment of depression, their side effects and adverse reactions are discussed specifically as these relate to the elderly. Suggestions are offered on how to improve safety and enhance compliance. Brief mention is made of the monoamine oxidase inhibitors and the second generation antidepressants. Dose ranges are recommended for use of these agents in geriatric patients. Finally, a section of the article reviews the most commonly encountered drug interactions between tricyclic and a variety of other psychotropic and nonpsychotropic drugs.
Get full access to this article
View all access options for this article.
References
1.
SchwabJ., Depression Among the Aged, Southern Medical Journal, 69, pp. 1039–1041, 1976.
2.
United States Department of Health, Education and Welfare, Vital Statistics of the United States, Vol. II, Mortality, Table 291A. Deaths for Suicide, by Five-year Age Groups, Color, and Sex: United States, 1968–1977. National Center for Health Statistics, Washington, D.C., 1980.
3.
WeissmanM. M. and MyersJ. K., Affective Disorders in a U.S. Urban Community, Archives of General Psychiatry, 35, pp. 1304–1311, 1978.
4.
SnyderS. H. and YamamuraH. I., Antidepressants and the Muscarinic Acetylcholine Receptor, Archives of General Psychiatry, 34, pp. 236–239, 1977.
5.
RathburnR. C. and SlaterI. H., Amitriptyline and Nortriptyline as Antagonists of Central and Peripheral Cholinergic Activation, Psychopharmacologia, 4, pp. 114–125, 1963.
6.
DuvoisinR. C., Glaucoma and Antiparkinsonism Drugs, Drug Therapy, pp. 23–26, February 1975.
7.
RischC. S.GroomG. P., and JanowskyD. S., The Effects of Psychotropic Drugs on the Cardiovascular System, Journal of Clinical Psychiatry, 43: 5, (Sec. 2), pp. 16–31, 1982.
8.
VeithR. C.RaskindM. A.CaldwellJ. H.BarnesR. F.GumprechtG., and RitchieJ. L., Cardiovascular Effects of Tricyclic Antidepressants in Depressed Patients with Chronic Heart Disease, New England Journal of Medicine, 306, pp. 954–959, 1982.
9.
BiggerJ. T.GiardinaE. V.PerelJ. M.KantorS. J., and GlassmanA. H., Cardiac Antiarrhythmic Effect of Imipramine Hydrochloride, New England Journal of Medicine, 296, pp. 206–207, 1977.
10.
GiardinaE. V.BiggerJ. T.GlassmanA. H.PerelJ. M., and KantorS. J., The Electrocardiographic and Antiarrhythmic Effects of Imipramine Hydrochloride at Therapeutic Plasma Concentrations, Circulation, 60, pp. 1045–1052, 1979.
11.
GiardinaE. V. and BiggerJ. T., Antiarrhythmic Effect of Imipramine Hydrocholoride in Patients with Ventricular Premature Complexes without Psychological Depression, American Journal of Cardiology, 50, pp. 172–179, 1982.
12.
EisdorferC. and FannW. (eds.), Psycho pharmacology and Aging, Plenum Press, New York, pp. 225–233, 1973.
13.
GlassmanA. H. and BiggerJ. T.Jr., Cardiovascular Effects of Therapeutic Doses of Tricyclic Antidepressants, Archives of General Psychiatry, 38, pp. 815–820, 1981.
14.
VohraJ.BurrowsG. D., and SlomanG., Assessment of Cardiovascular Side Effects of Therapeutic Doses of Tricyclic Antidepressant Drugs, Australia/New Zealand Journal of Medicine, 5, pp. 7–11, 1975.
15.
VohraJ.BurrowsG. D.HuntD., and SlomanG., The Effect of Toxic and Therapeutic Doses of Tricyclic Antidepressant Drugs on Intracardiac Conduction, European Journal of Cardiology, 3, pp. 219–227, 1975.
16.
BurrowsG. D.VohraJ.HuntD.SlomanJ. G.ScogginsB. A., and DaviesB., Cardiac Effects of Different Tricyclic Antidepressant Drugs, British Journal of Psychiatry, 129, pp. 335–341, 1976.
17.
JeffersonJ. W., A Review of the Cardiovascular Effects and Toxicity of Tricyclic Antidepressants, Psychosomatic Medicine, 37: 2, pp. 160–179, 1975.
18.
AydF. J., Long-Term Administration of Doxepin, Diseases of the Nervous System, 32, pp. 617–622, 1971.
19.
PinderR. M.BrogdenR. N.SpeightT. M., and AveryG. S., Doxepin Up-To-Date: A Review of Its Pharmacological Properties and Therapeutic Efficacy with Particular Reference to Depression, Drugs, 13, pp. 161–218, 1977.
AydF. J. (ed.), Maprotiline: An Effective Tetracyclic Antidepressant, International Drug Therapy Newsletter, 8, pp. 17–24, 1973.
22.
HattabJ. R., The Cardiovascular Effects of Ludiomil in Comparison with Those of Some Tricyclic Antidepressants, in Depression—The Biochemical and Physiological Role of Ludiomil, JukesA. (ed), Ciba Laboratories, Basel, pp. 191–200, 1976.
23.
BurckhardtD.RaederE.MullerV.ImhofP., and NeubauerH., Cardiovascular Effects of Tricyclic and Tetracyclic Antidepressants, Journal of the American Medical Association, 239: 3, pp. 213–216, 1978.
24.
MielkeD. H.KoepkeR. P., and PhillipsJ. H., A Controlled Evaluation of a Tetracyclic (Maprotiline) and a Tricyclic (Imipramine) Antidepressant and Their Effects on the Heart, Current Therapeutic Research, 25: 6, pp. 738–742, 1979.
25.
RealeA. and MotoleseM., Haemodynamische Studien mit Praparat CIBA 34–276-BA (Ludiomil), in Depressive Illness: Diagnosis, Assessment and Treatment, KielholzP. (ed.), Hans Huber, Bern, p. 161, 1972.
26.
BrunnerH.HedwallP. R.MeierM., and BeinH. J., Cardiovascular Effects of Preparation CIBA, 276-Ba and Imipramine, Agents Actions, 2, pp. 69–82, 1971.
27.
RaederE. A.ZinsliM., and BurckhardtD., Effect of Maprotiline on Cardiac Arrhythmias, British Medical Journal, 2: 102, 1979.
28.
AhlesS.GwirtsmanH.HalarisA.ShahP.SchwarczG., and HillM. A., Comparative Cardiac Effects of Maprotiline and Doxepin in Geriatric Depression, Journal of Clinical Psychiatry, 45, pp. 460–465, 1984.
29.
CairdF. I.AndrewsG. R., and KennedyR. D., Effect of Posture on Blood Pressure in the Elderly, British Heart Journal, 35, pp. 527–530, 1973.
30.
BlumenthalM. D. and DavieJ. W., Dizziness and Falling in Elderly Psychiatric Outpatients, American Journal of Psychiatry, 137, pp. 203–206, 1980.
31.
ThayssenP.BjerreM.Kragh-SorensenP.MollerM.PetersenO. L.KristensenC. B., and GramL. P., Cardiovascular Effects of Imipramine and Nortriptyline in Elderly Patients, Psychopharmacology, 74, pp. 360–364, 1981.
32.
NelsonJ. C.JatlowP. I.BockJ.QuinlanD. M., and BowersM. B., Major Adverse Reactions During Desipramine Treatment, Archives of General Psychiatry, 39, pp. 1055–1061, 1982.
33.
FriedelR. O., Pharmacokinetics in the Geropsychiatric Patient, in Psychopharmacology: A Generation of Progress, LiptonM. A.DiMascioA., and KillamK. F. (eds.), Raven Press, New York, pp. 1499–1505, 1978.
34.
CutlerN. R.ZavadilA. P.EisdorferC.RossR. J., and PotterW. Z., Concentrations of Desipramine in Elderly Women Are Not Elevated, American Journal of Psychiatry, 138, pp. 1235–1237, 1981.
35.
KitanakaI.RossR. J.CutlerN. R.ZavadilA. P., and PotterW. Z., Altered Hydroxydesipramine Concentrations in Elderly Depressed Patients, Clinical Pharmacological Therapy, 31, pp. 51–55, 1982.
36.
BunneyW. E. and GarlandB. L., Selected Aspects of Amine and Receptor Hypotheses of Affective Illness, Journal of Clinical Psychopharamcology, 1(6, Suppl.), pp. 3S–11S, 1981.
37.
AshfordJ. W. and FordC. V., Use of MAO Inhibitors in Elderly Patients, American Journal of Psychiatry, 136, pp. 1466–1467, 1979.
38.
GwirtsmanH.AhlesS.HalarisA.DeMetE., and HillM. A., Therapeutic Superiority of Maprotiline Versus Doxepin in Geriatric Patients, Journal of Clinical Psychiatry, 44, pp. 449–453, 1983.
39.
LitovitzT. L. and TroutmanW. G., Amoxapine Overdose: Seizures and Fatalities, Journal of the American Medical Association, 250, pp. 1069–1071, 1983.
40.
JeffersonJ. W., Convulsions Associated with Amoxapine, Journal of the American Medical Association, 251, p. 603, 1984.
41.
AydF. J., Amoxapine Side Effects: An Update, International Drug Therapy Newsletter, 19, pp. 21–23, 1984.
42.
TaylorD. P.HyslopD. K., and RibletL. A., Trazodone, A New Nontricyclic Antidepressant without Anticholinergic Activity, Biomedical Pharmacology, 29, pp. 2149–2150, 1980.
43.
GershonS. and NewtonR., Lack of Anticholinergic Side Effects with a New Antidepressant—Trazodone, Journal of Clinical Psychiatry, 41, pp. 100–104, 1980.
44.
HimmelhochJ. M., Cardiovascular Effects of Trazodone in Humans, Journal of Clinical Psychopharmacology, 1(6, Suppl.), pp. 76S–81S, 1981.
45.
JanowskyD.CurtisG.ZisookS.KuhnK.ResovskyK., and Le WinterM., Ventricular Arrhythmias Possibly Aggravated by Trazodone, American Journal of Psychiatry, 140, pp. 796–797, 1983.
46.
LippmanS.BedfordP.ManshadiM., and MatherS., Trazodone Cardiotoxicity, American Journal of Psychiatry, 140, p. 1383, 1983.
47.
BranconnierR. J.ColeJ. O.GhagvinianS.SperaK. F.OxenkrugG. F., and BassJ. L., Clinical Pharmacology of Bupropion and Imipramine in Elderly Depressives, Journal of Clinical Psychiatry, 44: 5(Sec 2), pp. 130–133, 1983.
48.
KaneJ. M.ColeK.SarantakosS.HowardA., and BorensteinM., Safety and Efficacy of Bupropion in Elderly Patients: Preliminary Observations, Journal of Clinical Psychiatry, 44: 5 (Sec. 2), pp. 134–136, 1983.
